Business Services · California, United States · 177 Employees
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector™ technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.Read More
Who is Biocept
Biocept , Inc Q3
Top Competitors of Biocept
Biocept Org Chart
Chief Executive Officer, Int...
Chief Operating Officer
Interim Chief Financial Offi...
Biocept Company Metrics
Total Funding Amount
Most Recent Funding Amount
Number of Funding Rounds
Biocept News & Media
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees. The inducement stock options have a grant date of February 28, 2023 and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4). The
Biocept to Lay Off 35 Percent of Staff, Explore Strategic Alternatives | GenomeWebThe company is hoping to preserve its cash runway and find a way to derive some value for its shareholders from its cerebrospinal fluid assay CNSide.
Biocept to Explore Strategic Alternatives and Implement Restructuring PlanSAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of a
Biocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call TranscriptBiocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call Transcript November 28, 2022 Operator: Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. And please note that this event is being recorded. I would now […]
Frequently Asked Questions regarding Biocept
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detect... Read More